Bio-Techne Q3 revenue down 2% to $311.4M, adj EPS $0.53; declares $0.08 dividend

BIO-TECHNE Corp

2026-Q3 EPS reported $0.81 revenue$893,847,000

Revenue $311.4M, down 2% reported and organic; GAAP EPS $0.32 (up from $0.14), adjusted EPS $0.53 (down from $0.56).
Large pharma grew double-digits for sixth consecutive quarter; U.S. academic market stabilized with low-single-digit growth; emerging biotech spending still lagging.
Protein Sciences segment sales $226.2M (down 1% reported); segment margin 44.2% vs 45.6%.
Diagnostics & Spatial Biology segment sales $85.6M (down 4% reported, up 3% organic); segment margin improved to 12.1% from 9.4%.
Declared quarterly dividend $0.08 per share, payable May 29, 2026 to shareholders of record May 18, 2026.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIO-TECHNE Corp reported financial results for quarter and nine months ended March 31, 2026.

Period: quarter and nine months ended March 31, 2026
Result: reported results

Exact text from the filing

A copy of the press release issued by Bio-Techne Corporation on May 6, 2026, describing the results of operations for the quarter and nine months ended March 31, 2026, and its financial condition as of March 31, 2026 is attached hereto as Exhibit 99.1.

View on SEC.gov

Browse all earnings releases →

BIO-TECHNE Corp filing history →

Source: SEC EDGAR

accession 0001104659-26-055887

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.